Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure-Reference-Cited by-同舟云学术

Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure

Published:2022-06 Issue:3 Volume:46 Page:100848
ISSN:0147-0272
Container-title:Current Problems in Cancer
language:en
Short-container-title:Current Problems in Cancer

Author:

Park Joo-Hwan^ORCID,Park Inkeun,Kim In-Ho,Hur Joon Young^ORCID,Hwang Inhwan,Kim Chan,Kim Hyo-Jeong^ORCID,Maeng Chi Hoon,Park Kwonoh^ORCID,Lee Min-Young,Lee Hyo Jin^ORCID,Jung Joo Young,Keam Bhumsuk,Park Se Hoon,Lee Jae Lyun

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Recently described and unusual variants of urothelial carcinoma of the urinary bladder;Samaratunga;Pathology,2012

3. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005

4. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options;Park;Korean J Intern Med,2020

5. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy;Bellmunt;Ann Oncol,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study;International Journal of Clinical Oncology;2024-06-04

2. The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real‐world multicenter analysis;Cancer Medicine;2024-01

3. Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study;Scientific Reports;2023-10-13

4. Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study;Scientific Reports;2023-10-03

5. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis;Clinical & Experimental Metastasis;2023-06-13